Merck

Merck HQ
#Harpoon Therapeutics #Immunotherapy #Merck #Mergers and acquisitions #Oncology

Merck continues to boost oncology pipeline through acquisitions

Merck (MSD), through a subsidiary, has agreed to acquire immunotherapy company Harpoon Therapeutics for $680 million. The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement follows the news that Merck agreed… Read More

#Business & Investment #News

Business agreement
#Colorectal cancer #Inspirna #License agreement #Merck #Oncology #Phase II trial

Merck expands colorectal cancer portfolio with ompenaclid

Merck has agreed a deal with Inspirna for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC). “Over the past… Read More

#Business & Investment #News

Research laboratory
#Cancer research #Collaboration #Merck #Oncology #The Institute of Cancer Research

ICR and Merck renew cancer drug discovery alliance

Merck and The Institute of Cancer Research (ICR), London, UK, have renewed their strategic alliance in the discovery and development of new cancer drugs. Scientists in the Centre for Cancer Drug Discovery at the ICR will work with researchers at Merck to discover and develop new… Read More

#Cancer Research #News

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

#Biologics #Collaboration #Ginkgo Bioworks #Merck

Ginkgo and Merck collaborate to improve biologic manufacturing 

Ginkgo Bioworks and Merck have collaborated to improve the production of biologics.  Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields.   “We’re thrilled to leverage our platform to… Read More

#News

#Astex Pharmaceuticals #Cancer research #Collaboration #Merck #Oncology

Astex and MSD expand cancer drug discovery collaboration

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. Under the terms of the agreement, Astex will apply its fragment-based drug discovery platform to develop compounds targeting multiple… Read More

#Business & Investment #News

Peptide
#Collaboration #Contract Research Organisations (CROs) #IRBM #Merck #Partnership #Peptides

IRBM and Merck extend peptide therapeutics collaboration

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. “The success of this collaboration is reflected by the outstanding achievements in the delivery of orally available peptide candidates,” said… Read More

#Business & Investment #News

Male patient with doctor
#AstraZeneca #FDA #Merck #Oncology #Phase III trial #Prostate cancer

FDA extends US approval for olaparib in prostate cancer

Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). The PARP inhibitor, developed by AstraZeneca and Merck (MSD), is approved in combination with abiraterone and prednisone or prednisolone. This approval was based on… Read More

#News #Regulatory

PD-L1 antibody
#Antibody #Cancer research #Collaboration #Merck #Oncology #Pfizer

Merck buys full rights to cancer drug Bavencio from Pfizer

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit… Read More

#Business & Investment #News

Non-small cell lung cancer
#Biomarkers #Lung cancer #Merck #Oncology #Phase II trial #Precision medicine #Regulatory #Scottish Medicines Consortium (SMC)

SMC approves targeted treatment for lung cancer

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.  … Read More

#News #Regulatory

Two scientists working in a research laboratory
#Antibody #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Merck #Mersana Therapeutics #Partnership #Tumours

Research partners hope to develop novel antibody-drug conjugates

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary… Read More

#Business & Investment #News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

Biosafety testing
#Biosafety testing #Expansion #Investment #Merck #US

Merck invests €290 million in biosafety testing

Merck has invested more than €290 million in its biosafety testing capacity at Rockville, Maryland, in the US.   The company says the investment will significantly increase the company’s ability to conduct biosafety testing and analytical development services, critical to the drug development and commercialisation process.  “These significant investments in Rockville… Read More

#Business & Investment #News

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

#Merck #Pharmaceutical research #R&D

Merck invests €160 million in new technology centre

Merck has opened a new Launch and Technology Center for healthcare in Darmstadt, costing the company around €160 million. This is part of a planned investment of more than €1.5 billion at the global headquarters in Darmstadt by 2025. The Launch and Technology Center will bridge research and commercial production… Read More

#News